Community Home

David Moolten, MD Medical Director American Red Cross United States Why the Quality and Make-up of Starting Material Matters The familiar truism garbage in, garbage out can be ruinously accurate in the setting of cell and gene therapy production. ...

Nathan Manley, PhD Senior Principal, Head of Nonclinical Dark Horse Consulting Group, Inc. United States Construction of an efficient, pressure-tested, development roadmap is an essential tool for preclinical cell and gene therapy (CGT) companies looking ...

For drug sponsors, setting up your CGT product for regulatory viability and commercial success means investing the time and budget to empower process design, as well as on-time planning of process performance qualification (PPQ) and continued process ...

From October 27–31, 2025, ISCT celebrated the successful conclusion of our 2025 Cell Therapy Leadership Training Program. Since its launch in 2015, this course has been a flagship initiative, cultivating the next generation of cell and gene therapy leaders ...

The International Society for Cell & Gene Therapy (ISCT), Alliance for Regenerative Medicine (ARM), and American Society of Gene & Cell Therapy (ASGCT) reaffirm our collective position, as articulated in the Cytotherapy editorial “ International ...